BioSpace News Archive

SOPHiA GENETICS (NASDAQ: SOPH) today announced that Jurgi Camblong, PhD., Chief Executive Officer and Co-founder, is scheduled to present at the J.P. Morgan 2024 Healthcare Conference on Thursday, January 11, 2024, at 9:00 a.m. PST in San Francisco.

B. Braun Medical Inc. (B. Braun), a leader in smart infusion therapy and pain management, announced today the launch of its new CARESITE Micro™ Luer Access Device, designed to reduce exposure to harmful chemicals and decrease infection risk, making IV access safer for patients and healthcare providers.

Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) today announced the U.S. Food and Drug Administration (FDA) has accepted the company’s Biologics License Application (BLA) for garadacimab (CSL312) as a once-monthly prophylactic treatment for hereditary angioedema (HAE).

Ionis Pharmaceuticals, Inc. announced the appointment of Michael Yang, an experienced biopharmaceutical executive, to the Ionis Board of Directors.

Heart Test Laboratories, Inc.d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”) today reported financial results for the second quarter fiscal 2024 ended October 31, 2023 and provided a business update.

Board of Directors approves increase in quarterly cash dividend to $0.42 per share Pfizer Inc. announced that its board of directors declared an increase in the quarterly cash dividend on the company’s common stock to $0.42 for the first-quarter 2024 dividend, payable March 1, 2024, to holders of the Common Stock of record at the close of business on January 26, 2024.

PTC Therapeutics, Inc. announced that on Dec. 10, 2023, the company approved non-statutory stock options to purchase an aggregate of 3,575 shares of its common stock and 3,035 restricted stock units, each representing the right to receive one share of its common stock upon vesting, to two new employees.

Karuna Therapeutics, Inc. (NASDAQ: KRTX), a biopharmaceutical company driven to discover, develop, and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced that results from the Phase 3 EMERGENT-2 trial of KarXT (xanomeline-trospium) in adults with schizophrenia were published in The Lancet.

Merck (NYSE: MRK) today announced that the U.S. Food and Drug Administration (FDA) has approved WELIREG, an oral hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor, for the treatment of adult patients with advanced renal cell carcinoma (RCC) following a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor and a vascular endothelial growth factor tyrosine kinase inhibitor (VEGF-TKI).

Novo Integrated Sciences, Inc. (NASDAQ:NVOS) (the “Company” or “Novo”) today reported its financial results for the fiscal year ended August 31, 2023.